Literature DB >> 25649760

Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros.

Maurizio Rossini1, Giovanni Orsolini, Ombretta Viapiana, Silvano Adami, Davide Gatti.   

Abstract

In glucocorticoid-induced osteoporosis (GIO), both bone formation and resorption are altered, however, with a relative prevalence of resorption, consistent with the positive results that have been reported with bisphosphonate treatment. Many studies have investigated the effect of bisphosphonates (BPs), a widely used class of anti-resorptive drugs, showing a positive effect on bone mineral density and fracture risk. Also in case of postmenopausal osteoporosis, the safety and cost-effectiveness profile of BPs in GIO appears good. Currently, the use of BPs is recommended at the earliest by all major scientific societies in postmenopausal women and men ≥50 years at high risk of fracture receiving glucocorticoid therapy. BPs are the most commonly used anti-osteoporotic agents and they remain the current standard of care for GIO.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25649760     DOI： 10.1007/s12020-014-0506-5

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


  56 in total

1.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

2.  Bone loss after glucocorticoid therapy.

Authors:  V Lo Cascio; E Bonucci; B Imbimbo; P Ballanti; D Tartarotti; G Galvanini; L Fuccella; S Adami
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

Review 3.  Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

Authors:  Maurizio Rossini; Davide Gatti; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

4.  Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells.

Authors:  J Rubin; D M Biskobing; L Jadhav; D Fan; M S Nanes; S Perkins; X Fan
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

5.  Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

Authors:  C Roux; P Oriente; R Laan; R A Hughes; J Ittner; S Goemaere; O Di Munno; J M Pouillès; S Horlait; B Cortet
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

Review 6.  Glucocorticoid-induced osteoporosis: an update.

Authors:  Gherardo Mazziotti; Alberto Angeli; John P Bilezikian; Ernesto Canalis; Andrea Giustina
Journal:  Trends Endocrinol Metab       Date:  2006 May-Jun       Impact factor: 12.015

7.  Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Authors:  O Ström; F Borgström; S S Sen; S Boonen; P Haentjens; O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2007-02-28       Impact factor: 4.507

8.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; F Sorenson
Journal:  Osteoporos Int       Date:  2003-08-28       Impact factor: 4.507
View more
  3 in total

Review 1.  Current Status of Research on Osteoporosis after Solid Organ Transplantation: Pathogenesis and Management.

Authors:  Gong-bin Lan; Xu-biao Xie; Long-kai Peng; Lei Liu; Lei Song; He-long Dai
Journal:  Biomed Res Int       Date:  2015-11-15       Impact factor: 3.411

2.  Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis.

Authors:  Liwei Yao; Haiqing Wang; Wenwei Dong; Zhenxin Liu; Haijiao Mao
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

3.  Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.

Authors:  Jing Deng; Zhengping Feng; Yue Li; Tingting Pan; Qifu Li; Changhong Zhao
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.